Early diagnosis of non-alcoholic fatty liver disease: the role of biomarkers and complex indices of non-alcoholic fatty liver steatosis

L. V. Tarasova, Yu. V. Tsyganova
{"title":"Early diagnosis of non-alcoholic fatty liver disease: the role of biomarkers and complex indices of non-alcoholic fatty liver steatosis","authors":"L. V. Tarasova, Yu. V. Tsyganova","doi":"10.31146/1682-8658-ecg-216-8-27-36","DOIUrl":null,"url":null,"abstract":"Metabolic syndrome is a series of pathologies united by a similar pathogenesis, the end of which, most often, is cardiovascular accidents, which are leaders among the causes of death in the population around the world. Non-alcoholic fatty liver disease (NAFLD) is the hepatic equivalent of the metabolic syndrome, registered earlier than all other equivalents, on the rights of the liver as a first-line energy depot. At the same time, according to multicenter studies, 95% of people with NAFLD (any stage) are not diagnosed with the disease. Clarification of additional risk factors for NAFLD and the presence of a specific biomarker of non-alcoholic liver steatosis would make it possible to stop the vicious cascade of metabolic processes, which in the future can lead to a significant increase in the life expectancy of the population. The potentially high role of Secreted Frizzled Related Protein-4 (SFRP4) adipokine in the early diagnosis of NAFLD is known. The aim of the study was to optimize the early diagnosis of non-alcoholic fatty liver disease using modern indices and biomarkers. Materials and methods. The work was carried out at the Department of Faculty and Hospital Therapy of the Chuvash State University named after I. N. Ulyanov” in the period from 2016 to 2020. This study included several stages: first of all, a retrospective analysis of 1150 outpatient records of patients from several medical organizations of the Chuvash Republic for the period 2016-2018 was carried out. to form two study groups: experimental and control. At the second stage, as a result of applying the exclusion criteria, 162 people remained in the experiment: 110 from the experimental group, 52 from the control group. The subjects of both groups were compared by gender and age, the age range of the subjects varied from 18 to 80 years old with an average value of 48.3 years. Further, the patients undergo a detailed examination, according to the presented plan: Collection of complaints, medical history, objective examination. Laboratory studies (general and biochemical blood tests, lipidogram, assessment of the level of serum adipokine SFRP4). Instrumental studies (ultrasound of the OBP, TE (SAR), ESP with elastometry). Evaluation of the most informative complex indices for the early diagnosis of NAFLD: MI, IVO indices, HSI, FLD-I. Further, all the necessary statistical processing and analysis of the obtained data were performed (Microsoft Office Excel 2016, StatTech v. 2.8.8 (developer - Stattech LLC, Russia)). Results. Accessible (not requiring the use of additional time and material costs) NAFLD indices with the highest sensitivity rates (99.1% and 98.2%, respectively) were MI and IVO. A noticeable direct correlation was traced between MI (p=0.640), moderate - between the IVO (p=0.398) and the elastographically determined index of non-alcoholic liver steatosis. High sensitivity and specificity of skin manifestations (xanthoma, xanthelasma - 69.6% and 89.7% and seborrheic dermatitis - 82.0% and 71.4%) were found in relation to early manifestations of NAFLD. From anthropometric indicators: the CW/CF index has a pronounced (ρ=0.643), CW - moderate (ρ=0.238), and BMI - a weak direct (ρ=0.223) correlation with the elastographically determined index of non-alcoholic liver steatosis. Adipokine SFRP4 correlates (ρ=0.841) with early manifestations of hepatic steatosis in patients, as determined by TE in CAP mode.","PeriodicalId":11555,"journal":{"name":"Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31146/1682-8658-ecg-216-8-27-36","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Metabolic syndrome is a series of pathologies united by a similar pathogenesis, the end of which, most often, is cardiovascular accidents, which are leaders among the causes of death in the population around the world. Non-alcoholic fatty liver disease (NAFLD) is the hepatic equivalent of the metabolic syndrome, registered earlier than all other equivalents, on the rights of the liver as a first-line energy depot. At the same time, according to multicenter studies, 95% of people with NAFLD (any stage) are not diagnosed with the disease. Clarification of additional risk factors for NAFLD and the presence of a specific biomarker of non-alcoholic liver steatosis would make it possible to stop the vicious cascade of metabolic processes, which in the future can lead to a significant increase in the life expectancy of the population. The potentially high role of Secreted Frizzled Related Protein-4 (SFRP4) adipokine in the early diagnosis of NAFLD is known. The aim of the study was to optimize the early diagnosis of non-alcoholic fatty liver disease using modern indices and biomarkers. Materials and methods. The work was carried out at the Department of Faculty and Hospital Therapy of the Chuvash State University named after I. N. Ulyanov” in the period from 2016 to 2020. This study included several stages: first of all, a retrospective analysis of 1150 outpatient records of patients from several medical organizations of the Chuvash Republic for the period 2016-2018 was carried out. to form two study groups: experimental and control. At the second stage, as a result of applying the exclusion criteria, 162 people remained in the experiment: 110 from the experimental group, 52 from the control group. The subjects of both groups were compared by gender and age, the age range of the subjects varied from 18 to 80 years old with an average value of 48.3 years. Further, the patients undergo a detailed examination, according to the presented plan: Collection of complaints, medical history, objective examination. Laboratory studies (general and biochemical blood tests, lipidogram, assessment of the level of serum adipokine SFRP4). Instrumental studies (ultrasound of the OBP, TE (SAR), ESP with elastometry). Evaluation of the most informative complex indices for the early diagnosis of NAFLD: MI, IVO indices, HSI, FLD-I. Further, all the necessary statistical processing and analysis of the obtained data were performed (Microsoft Office Excel 2016, StatTech v. 2.8.8 (developer - Stattech LLC, Russia)). Results. Accessible (not requiring the use of additional time and material costs) NAFLD indices with the highest sensitivity rates (99.1% and 98.2%, respectively) were MI and IVO. A noticeable direct correlation was traced between MI (p=0.640), moderate - between the IVO (p=0.398) and the elastographically determined index of non-alcoholic liver steatosis. High sensitivity and specificity of skin manifestations (xanthoma, xanthelasma - 69.6% and 89.7% and seborrheic dermatitis - 82.0% and 71.4%) were found in relation to early manifestations of NAFLD. From anthropometric indicators: the CW/CF index has a pronounced (ρ=0.643), CW - moderate (ρ=0.238), and BMI - a weak direct (ρ=0.223) correlation with the elastographically determined index of non-alcoholic liver steatosis. Adipokine SFRP4 correlates (ρ=0.841) with early manifestations of hepatic steatosis in patients, as determined by TE in CAP mode.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非酒精性脂肪肝疾病的早期诊断:非酒精性脂肪肝脂肪变性的生物标志物和复杂指标的作用
代谢综合征是由一个相似的发病机制联合起来的一系列病理,最后,最常见的是心血管事故,这是世界上人口死亡的主要原因。非酒精性脂肪性肝病(NAFLD)是代谢综合征的肝脏等效物,比所有其他等效物更早登记,是肝脏作为第一线能量储存的权利。与此同时,根据多中心研究,95%的NAFLD患者(任何阶段)未被诊断出患有该疾病。澄清NAFLD的其他危险因素和非酒精性肝脂肪变性的特定生物标志物的存在,将有可能阻止代谢过程的恶性级联反应,这在未来可能导致人口预期寿命的显着增加。分泌卷曲相关蛋白4 (SFRP4)脂肪因子在NAFLD早期诊断中的潜在高作用是已知的。该研究的目的是利用现代指标和生物标志物优化非酒精性脂肪性肝病的早期诊断。材料和方法。这项工作于2016年至2020年期间在以乌里扬诺夫命名的楚瓦什国立大学教师和医院治疗系进行。本研究包括几个阶段:首先,对2016-2018年期间来自楚瓦什共和国几家医疗机构的1150例患者门诊记录进行回顾性分析。分成两个研究组:实验组和对照组。在第二阶段,由于应用了排除标准,162人仍然留在实验中:实验组110人,对照组52人。两组受试者按性别、年龄进行比较,受试者年龄从18岁到80岁不等,平均值为48.3岁。此外,根据提出的计划,对患者进行详细检查:收集投诉、病史、客观检查。实验室检查(一般和生化血液检查、血脂检查、血清脂肪因子SFRP4水平评估)。仪器研究(OBP超声,TE (SAR), ESP弹性测量)。评价NAFLD早期诊断最具信息量的复杂指标:MI、IVO指数、HSI、FLD-I。此外,对获得的数据进行所有必要的统计处理和分析(Microsoft Office Excel 2016, StatTech v. 2.8.8(开发商- StatTech LLC, Russia))。结果。敏感度最高(分别为99.1%和98.2%)的NAFLD指标为MI和IVO(无需额外的时间和物质成本)。MI (p=0.640)、IVO (p=0.398)与弹性成像测定的非酒精性肝脂肪变性指数之间存在显著的直接相关性。皮肤表现(黄瘤、黄斑瘤分别为69.6%和89.7%,脂溢性皮炎分别为82.0%和71.4%)与NAFLD早期表现有较高的敏感性和特异性。从人体测量指标来看:CW/CF指数与弹性学测定的非酒精性肝脂肪变性指数有明显的(ρ=0.643)、CW -中度(ρ=0.238)和BMI -微弱的直接相关性(ρ=0.223)。脂肪因子SFRP4与患者肝脂肪变性的早期表现相关(ρ=0.841),由TE在CAP模式下确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Enterohepatocentrism as the basis of human psychosomatic pathology Anatoly Afanasyevich Ilchenko (1946-2013) in memory of a teacher Biliary gastritis. Pathomorphological features and differential diagnosis The debut of autoimmune hepatitis after a new coronavirus infection (COVID-19) in an 11-month-old child Functional gastrointestinal disorders in patients with chronic opisthorchiasis and rosacea
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1